STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2002-06-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-002-0469-8PMID 12172978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

  2004cited by this paper
• Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma.

  2000cited by this paper
• Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer

  2000cited by this paper
• Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice

  1999cited by this paper
• Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.

  1999cited by this paper
• Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats.

  1998cited by this paper
• Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.

  1998cited by this paper
• Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996).

  1998cited by this paper
• Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993).

  1996cited by this paper
• Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.

  1995cited by this paper
• Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

  1994cited by this paper
• Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue.

  1993cited by this paper
• Measurement of material extravasation in microvascular networks using fluorescence video-microscopy.

  1993cited by this paper
• Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990).

  1992cited by this paper
• Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988).

  1992cited by this paper
• Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

  1991cited by this paper
• Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.

  1991cited by this paper
• Amputation and cisplatin for treatment of canine osteosarcoma.

  1991influential reference
• Toxicity of platinum based anticancer drugs

  1991cited by this paper
• Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.

  1989cited by this paper
• Liposomes as drug carrier system for cis-diamminedichloroplatinum (II)

  1988cited by this paper
• Evaluation of a short-term saline diuresis protocol for the administration of cisplatin.

  1988cited by this paper
• Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules.

  1988cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• 7 Canine Osteosarcoma: A Clinicopathologic Study of 194 Cases

  1969cited by this paper

• Effects of trastuzumab emtansine on canine osteosarcoma cells

  2025cites this paper
• Platinum-based chemotherapy: trends in organic nanodelivery systems.

  2024cites this paper
• A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy

  2022cites this paper
• The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.

  2022cites this paper
• Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs

  2022cites this paper
• Nanocarriers in Veterinary Medicine: A Challenge for Improving Osteosarcoma Conventional Treatments

  2022cites this paper
• Musculoskeletal Tumors

  2022cites this paper
• Recent advances in microencapsulation of drugs for veterinary applications.

  2021cites this paper
• In Vitro Anticancer Activity of Nanoformulated Mono- and Di-nuclear Pt Compounds.

  2021cites this paper
• Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas

  2021cites this paper
• Controlled Drug Delivery Vehicles in Veterinary Oncology: State-of-the-Art and Future Directions

  2020influential citation
• Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma.

  2020cites this paper
• Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma

  2020cites this paper
• Biological behavior of primary osteosarcoma of the digits, metacarpal and metatarsal bones in dogs.

  2020cites this paper
• YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells

  2019cites this paper
• Clinical Trials and Developmental Therapeutics

  2019cites this paper
• Canine Cancer: Strategies in Experimental Therapeutics

  2019cites this paper
• Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.

  2018cites this paper
• Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma

  2018cites this paper
• Comparative oncology: Integrating human and veterinary medicine

  2018cites this paper
• Canine sarcomas as a surrogate for the human disease

  2018cites this paper
• The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats

  2017cites this paper
• hich dogs with appendicular osteosarcoma benefit most from hemotherapy after surgery ? Results from an individual patient data eta-analysis

  2016cites this paper
• Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs

  2016cites this paper
• Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study.

  2016cites this paper
• University of Groningen Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery ?

  2016cites this paper
• Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma

  2016cites this paper
• 3-octadecylcarbamoylacrylic acid-cisplatin nanocomplexes for the development of novel liposome formulation

  2016cites this paper
• Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis.

  2016cites this paper
• Liposomal Membrane Modification, Polymers for

  2015cites this paper
• Nanomedicine in veterinary oncology.

  2015cites this paper
• Combined treatment of canine osteosarcoma cells with gene knock-down and chemotherapy

  2014cites this paper
• Effect Modification of Interventions. Bridging the Gap Between Clinical Studies and the Individual Patient

  2014cites this paper
• Nanomedicines in the future of pediatric therapy.

  2014cites this paper
• Regulatory Aspects of Oncologicals: Nanosystems Main Challenges

  2014cites this paper
• Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy.

  2014cites this paper
• Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?

  2014cites this paper
• What do we know about canine osteosarcoma treatment? – review

  2014cites this paper
• Canine prostate: would the dog be an important model for the study of new drugs?

  2013cites this paper
• Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis.

  2013cites this paper
• 17 – Clinical Trials and Developmental Therapeutics

  2013cites this paper
• Met interacts with EGFR and Ron in canine osteosarcoma.

  2013cites this paper
• Survival times for canine intranasal sarcomas treated with radiation therapy: 86 cases (1996-2011).

  2013cites this paper
• Tumors of the Skeletal System

  2012cites this paper
• Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity

  2012cites this paper
• Koiran osteosarkooma - kirjallisuuskatsaus

  2012cites this paper
• Evaluation of a single subcutaneous infusion of carboplatin as adjuvant chemotherapy for dogs with osteosarcoma: 17 cases (2006-2010).

  2012cites this paper
• Nanomedicine and veterinary science: the reality and the practicality.

  2012cites this paper
• Prognostic factors in canine appendicular osteosarcoma – a meta-analysis

  2012cites this paper
• Low-dose chemotherapy for canine appendicular osteosarcoma

  2011cites this paper
• Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations

  2011cites this paper
• Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?

  2011cites this paper
• Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006).

  2011cites this paper
• Encapsulation of vinorelbine into cholesterol‐polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies

  2011cites this paper
• Targeting Strategies for Metal‐Based Therapeutics

  2011cites this paper
• Nanoscale Delivery Systems for Combination Chemotherapy

  2011cites this paper
• Using liposomes to target infection and inflammation induced by foreign body injuries or medical implants

  2010cites this paper
• Canine T-regulatory cells in aging and cancer : quantifying a unique T cell subset

  2010cites this paper
• The status of platinum anticancer drugs in the clinic and in clinical trials.

  2010cites this paper
• Liposomal cancer therapy: exploiting tumor characteristics

  2010cites this paper
• A novel micelle-encapsulated platinum(II) anticancer agent.

  2010cites this paper
• Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.

  2010cites this paper
• Functional liposomal membranes for triggered release.

  2010cites this paper
• Prognostic and predictive biomarkers of canine osteosarcoma.

  2010cites this paper
• CANINE T-REGULATORY CELLS IN AGING AND CANCER: QUANTIFYING A UNIQUE T CELL SUBSET

  2010cites this paper
• Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs.

  2009cites this paper
• Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.

  2009cites this paper
• How companion animals contribute to the fight against cancer in humans.

  2009cites this paper
• Ultrasound triggered release of cisplatin from liposomes in murine tumors.

  2009cites this paper
• Cisplatin: a review of toxicities and therapeutic applications.

  2008cites this paper
• Development of cancer diagnostics using nanoparticles and amphiphilic polymers

  2008cites this paper
• Pharmacokinetics and biodistribution of nanoparticles.

  2008cites this paper
• Nanocapsules: a novel formulation technology for platinum-based anticancer drugs

  2007cites this paper
• Nanocapsules: A Novel Lipid Formulation Platform for Platinum-based Anti-cancer Drugs

  2007cites this paper
• Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study.

  2007cites this paper
• Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients.

  2007cites this paper
• Cancer clinical trials: development and implementation.

  2007cites this paper
• Oncology of companion animals as a model for humans. an overview of tumor histotypes.

  2006cites this paper
• Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.

  2005cites this paper
• Cytotoxic chemotherapy: new players, new tactics.

  2005cites this paper
• Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity

  2005cites this paper
• In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

  2004cites this paper
• Le carboplatine en chimiothérapie vétérinaire, revue bibliographique et application à 11 cas de tumeurs des cavités nasales chez le chien

  2004cites this paper
• RNA Interference: A Potent Tool for Gene‐Specific Therapeutics

  2004cites this paper
• Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.

  2004cites this paper
• Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development

  2004cites this paper
• Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.

  2004cites this paper
• Update on the biology and management of canine osteosarcoma.

  2003cites this paper
• Cisplatin and platinum drugs at the molecular level. (Review).

  2003cites this paper
• chemo-Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996–2006)

  year unknowncites this paper